Stereotaxis(STXS) - 2025 Q4 - Annual Report

Financial Performance and Backlog - As of December 31, 2025, the company had approximately $9.1 million in system backlog, with an expectation that about 78% will be recognized as revenue in 2026[26] - The company reported a system backlog of approximately $14.4 million as of December 31, 2024, indicating growth in demand for its products[26] Acquisitions and Product Development - The company completed the acquisition of Access Point Technologies EP, Inc. on July 31, 2024, enhancing its in-house catheter development capabilities[28] - The acquisition of Access Point Technologies EP, Inc. on July 31, 2024, provides the company with the Map-iT portfolio, enhancing its offerings in traditional cardiac ablation procedures[43] - The MAGiC Sweep catheter received FDA 510(k) clearance in July 2025, marking a significant advancement in the company's product lineup[52] - The company has developed a proprietary MAGiC ablation catheter expected to receive regulatory clearance in Europe by 2025 and in the U.S. by early 2026, which will replace the currently used J&J catheters[67] Clinical Focus and Market Potential - The primary clinical focus is on electrophysiology, specifically cardiac ablation procedures, which represent a multi-billion-dollar market with significant growth potential[19] - The market for cardiac ablation procedures has grown rapidly, with an annualized procedure growth rate of approximately 10%[57] - The company estimates that approximately 4 million interventional cardiology procedures are performed annually in the U.S., with 10-15% classified as complex, requiring longer procedure times and potentially sub-optimal outcomes[63] Technology and Innovation - The GenesisX RMN System is designed to improve accessibility and reduce installation time compared to previous generations[22] - The Odyssey Solution and its next-generation counterparts, Synchrony and SynX, aim to enhance procedure efficiency and lab integration[23] - The robotic technology is expected to enable more complex procedures with improved patient outcomes and reduced x-ray exposure[33] - The robotic technology has been demonstrated in over 500 publications and more than 150,000 procedures, showing significant reductions in major complications and patient radiation exposure[36] - The Odyssey Solution integrates multiple diagnostic and imaging sources into a single user interface, improving clinical workflow and efficiency in interventional labs[39] Regulatory and Compliance - The company’s medical devices are subject to extensive regulation by the FDA, requiring 510(k) clearance or pre-market approval (PMA) for commercial marketing in the U.S.[99][101] - Most of the company's current products are classified as Class II devices requiring 510(k) clearances, while certain therapeutic devices are classified as Class III and require PMA[102] - The 510(k) clearance process typically takes between four to twelve months, but can take longer depending on the complexity of the device[104] - The company must comply with various international regulations, including obtaining CE Mark certification for marketing in the European Economic Area[110] - The company is subject to anti-kickback and false claims laws, which impose significant penalties for violations related to healthcare fraud and abuse[112] Competition and Market Position - The company faces competition from traditional catheter-based electrophysiology approaches and new products in the market, including next-generation mapping systems and non-RF ablation devices[94] - The company faces competition from four companies with FDA-cleared endovascular catheter navigation systems for electrophysiology procedures and two companies with CE Mark approved electromagnetic catheter navigation systems in Europe[95] - The company has developed its own line of robotically enabled medical devices, competing with other manufacturers of traditional interventional devices and magnetically enabled catheters[96] - The Odyssey/Synchrony Solution faces direct competition from established imaging companies and dedicated solution providers, with expectations of continued competitive pressure due to rapid technological advancements[97] - Key competitive factors in the market include capability, safety, efficacy, ease of use, price, quality, reliability, and effective sales support[98] Workforce and Employee Relations - As of December 31, 2025, the company had 131 employees, with 40 in research and development, 47 in sales and marketing, 26 in manufacturing and service, and 18 in general administrative activities[125] - The company emphasizes the importance of attracting and retaining top talent to succeed in the competitive medical device industry[122] - The company provides a comprehensive total rewards package, including annual bonuses, sales commissions, and a 5% discount on stock purchases for eligible employees[128] - The company emphasizes employee health and wellness, offering programs that support mental health, family care, and financial well-being[126] - The company engages in ongoing training and development, requiring compliance training and offering professional development courses[129] - The company maintains a positive relationship with employees, with a significant majority not covered by collective bargaining agreements[125] - The company operates in 11 different countries, reflecting a diverse global workforce[124] - The company is committed to fostering a culture of mutual respect and dignity among employees[124] - The company conducts annual global performance reviews to assess employee performance and compensation[129] - The company invests in employee safety and wellness programs, adhering to regional and local regulations[127] Transparency and Communication - The company makes SEC filings available on its website, ensuring transparency and accessibility of financial information[130]